Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913664 · ClinicalTrials.gov registry record · Phase 2
Risk Reduction for Alzheimer's Disease
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 513
- Enrollment target
NCT02913664: Completed Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT02913664 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 513 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (286% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02913664, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 513 participants
- Enrollment target
Study Summary
Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with lifestyle changes, pharmacological treatment, or both. The rrAD study will determine effects of aerobic exercise training and intensive vascular risk reduction on cognitive performance in older adults who have high risk for AD.
Primary Outcome
Alzheimer's Disease Cooperative Study-Preclinical Alzheimer Cognitive Composite (ADCS-PACC) and NIH Toolbox (NIH-TB) Cognition Battery will be used to assess changes in neurocognitive function. The composite z-score for global cognition will be obtained by conversion of individual test scores to the standardized z-scores, then averaged to obtain a composite score.
Interventions
- OTHER Usual Care
- BEHAVIORAL Aerobic Exercise Training
- DRUG Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
- BEHAVIORAL Stretching Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
What the finished NCT02913664 record still lists
NCT02913664 is an interventional study that assigns participants to a tested intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (286% higher).
The record links to 0 conditions, and to 4 interventions - of which Usual Care is the first listed.
NCT02913664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02913664 about?
NCT02913664 is a clinical study titled "Risk Reduction for Alzheimer's Disease". Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with lifestyle changes, pharmacological treatment, or both. The rrAD study will determine effects of aerobic exercise training...
What is the current status of trial NCT02913664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 513 participants. The study started on 2017-02-02. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT02913664?
The interventions under investigation include: Usual Care (OTHER), Aerobic Exercise Training (BEHAVIORAL), Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) (DRUG), Stretching Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT02913664?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02913664's enrollment target sits among peer trials
513 67th of 2000 higher than 1,934 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI